Lv31
320 积分 2022-06-22 加入
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision
3个月前
已完结
Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update
3个月前
已完结
Osteoporotic fractures: an unrecognized adverse event of immune checkpoint inhibitors?
3个月前
已完结
Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee
3个月前
已完结
Merkel cell carcinoma refractory to anti-PD(L)1: utility of adding ipilimumab for salvage therapy
3个月前
已完结
Gene panel predicts neoadjuvant chemoimmunotherapy response and benefit from immunotherapy in HER2-negative breast cancer
3个月前
已完结
Epithelium/imcDC2 axis facilitates the resistance of neoadjuvant anti-PD-1 in human NSCLC
3个月前
已完结
An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade
3个月前
已完结
Targeting TNFRSF25 by agonistic antibodies and multimeric TL1A proteins co-stimulated CD8+T cells and inhibited tumor growth
3个月前
已完结
NR4A ablation improves mitochondrial fitness for long persistence in human CAR-T cells against solid tumors
3个月前
已完结
皖公网安备34019202002308
